Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I
- PMID: 7823972
- DOI: 10.1002/mus.880180202
Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I
Abstract
The etiology of the Guillain-Barré syndrome (GBS) still remains elusive. Recent years have witnessed important advances in the delineation of the mechanisms that may operate to produce nerve damage. Evidence gathered from cell biology, immunology, and immunopathology studies in patients with GBS and animals with experimental autoimmune neuritis (EAN) indicate that GBS results from aberrant immune responses against components of peripheral nerve. Autoreactive T lymphocytes specific for the myelin antigens P0 and P2 and circulating antibodies to these antigens and various glycoproteins and glycolipids have been identified but their pathogenic role remains unclear. The multiplicity of these factors and the involvement of several antigen nonspecific proinflammatory mechanisms suggest that a complex interaction of immune pathways results in nerve damage. Data on disturbed humoral immunity with particular emphasis on glycolipid antibodies and on activation of autoreactive T lymphocytes and macrophages will be reviewed. Possible mechanisms underlying initiation of peripheral nerve-directed immune responses will be discussed with particular emphasis on the recently highlighted association with Campylobacter jejuni infection.
Similar articles
-
[New aspects of the pathogenesis and therapy of Guillain-Barré syndrome and chronic polyneuritis].Nervenarzt. 1990 Apr;61(4):197-207. Nervenarzt. 1990. PMID: 2191228 Review. German.
-
[Guillain-Barré syndrome and acute disseminated encephalomyelitis (ADEM)].Rinsho Shinkeigaku. 1996 Dec;36(12):1301-7. Rinsho Shinkeigaku. 1996. PMID: 9128388 Review. Japanese.
-
Inhibition of experimental autoimmune neuritis by an antibody to the lymphocyte function-associated antigen-1.Lab Invest. 1994 May;70(5):667-75. Lab Invest. 1994. PMID: 8196363
-
Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part II.Muscle Nerve. 1995 Feb;18(2):154-64. doi: 10.1002/mus.880180203. Muscle Nerve. 1995. PMID: 7823973 Review.
-
The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders.Ann Neurol. 1993 Aug;34(2):136-44. doi: 10.1002/ana.410340208. Ann Neurol. 1993. PMID: 8338338
Cited by
-
Anti-ganglioside antibodies alter presynaptic release and calcium influx.Neurobiol Dis. 2007 Oct;28(1):113-21. doi: 10.1016/j.nbd.2007.07.008. Epub 2007 Jul 14. Neurobiol Dis. 2007. PMID: 17720506 Free PMC article.
-
Tumour necrosis factor α enhances CCL2 and ICAM-1 expression in peripheral nerve microvascular endoneurial endothelial cells.ASN Neuro. 2013 Feb 6;5(1):e00104. doi: 10.1042/AN20120048. ASN Neuro. 2013. PMID: 23293927 Free PMC article.
-
Granulocyte-colony-stimulating factor treatment enhances Foxp3(+) T lymphocytes and modifies the proinflammatory response in experimental autoimmune neuritis.CNS Neurosci Ther. 2013 Jul;19(7):529-32. doi: 10.1111/cns.12112. Epub 2013 May 3. CNS Neurosci Ther. 2013. PMID: 23638874 Free PMC article. No abstract available.
-
Mechanisms of immune regulation in the peripheral nervous system.Brain Pathol. 1999 Apr;9(2):343-60. doi: 10.1111/j.1750-3639.1999.tb00231.x. Brain Pathol. 1999. PMID: 10219750 Free PMC article. Review.
-
Transfer of myelin-specific cells deviated in vitro towards IL-4 production ameliorates ongoing experimental allergic neuritis.Clin Exp Immunol. 2001 Jan;123(1):112-8. doi: 10.1046/j.1365-2249.2001.01424.x. Clin Exp Immunol. 2001. PMID: 11168007 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources